A Study of Induction and Maintenance Treatment With MabThera (Rituximab) in Patients With Indolent B-Cell Nonfollicular Lymphomas

This study has been completed.
Information provided by (Responsible Party):
Hoffmann-La Roche
ClinicalTrials.gov Identifier:
First received: June 14, 2010
Last updated: October 8, 2013
Last verified: October 2013

This study will evaluate the efficacy and safety of MabThera in combination chemotherapy, followed by maintenance treatment with MabThera. The anticipated time on study treatment is 1-2 years, and the target sample size is <100 individuals.

Condition Intervention Phase
Non-Hodgkin's Lymphoma
Drug: rituximab
Phase 2

Study Type: Interventional
Study Design: Allocation: Non-Randomized
Endpoint Classification: Safety/Efficacy Study
Intervention Model: Single Group Assignment
Masking: Open Label
Primary Purpose: Treatment
Official Title: An Open-label Study of Fludarabine and Cyclophosphamide Plus MabThera Followed by Maintenance With MabThera on Failure-free Survival in Treatment-naïve Patients With Advanced Indolent B-cell Nonfollicular Lymphoma

Resource links provided by NLM:

Further study details as provided by Hoffmann-La Roche:

Primary Outcome Measures:
  • Failure-free survival [ Time Frame: From first patient enrolled to approximately 42 months ] [ Designated as safety issue: No ]

Secondary Outcome Measures:
  • Overall survival [ Time Frame: From first patient enrolled to approximately 42 months ] [ Designated as safety issue: No ]
  • Disease-free survival [ Time Frame: From first patient enrolled to approximately 42 months ] [ Designated as safety issue: No ]
  • Duration of response [ Time Frame: From first patient enrolled to approximately 42 months ] [ Designated as safety issue: No ]
  • Response rate [ Time Frame: From first patient enrolled to approximately 42 months ] [ Designated as safety issue: No ]
  • Incidence of adverse events [ Time Frame: From first patient enrolled to approximately 42 months ] [ Designated as safety issue: No ]

Enrollment: 47
Study Start Date: July 2005
Study Completion Date: September 2010
Primary Completion Date: September 2010 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: 1 Drug: rituximab
Other Name: MabThera/Rituxan


Ages Eligible for Study:   18 Years to 65 Years
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • adult patients 18-65 years of age;
  • previously untreated indolent nonfollicular non-Hodgkin's lymphoma;
  • active disease;
  • >=3 involved sites.

Exclusion Criteria:

  • typical chronic lymphocytic leukemia;
  • other malignancies within 3 years before study, except basal or squamous cell skin cancer or cancer in situ of the cervix;
  • systemic corticosteroid use for >1 month;
  • significant cardiovascular disease;
  • central nervous system involvement;
  • hepatitis B or C virus infection, or HIV infection.
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT01153971

Alessandria, Italy, 15100
Brescia, Italy, 25123
Cuneo, Italy, 12100
Firenze, Italy, 50135
Messina, Italy, 98165
Milano, Italy, 20122
Milano, Italy, 20162
Modena, Italy, 41100
Pescara, Italy, 65124
Pescara, Italy, 65100
Reggio Calabria, Italy, 89100
Reggio Emilia, Italy, 42100
Rionero in Vulture, Italy, 85028
Roma, Italy, 00161
Torino, Italy, 10126
Sponsors and Collaborators
Hoffmann-La Roche
Study Chair: Clinical Trials Hoffmann-La Roche
  More Information

No publications provided

Responsible Party: Hoffmann-La Roche
ClinicalTrials.gov Identifier: NCT01153971     History of Changes
Other Study ID Numbers: ML18324
Study First Received: June 14, 2010
Last Updated: October 8, 2013
Health Authority: Italy: Ministry of Health

Additional relevant MeSH terms:
Lymphoma, Non-Hodgkin
Neoplasms by Histologic Type
Lymphoproliferative Disorders
Lymphatic Diseases
Immunoproliferative Disorders
Immune System Diseases
Immunologic Factors
Physiological Effects of Drugs
Pharmacologic Actions
Antirheumatic Agents
Therapeutic Uses
Antineoplastic Agents

ClinicalTrials.gov processed this record on July 28, 2014